Literature DB >> 2579829

Inhibition of IgE-mediated mast cell degranulation by sulphasalazine.

K E Barrett, T L Tashof, D D Metcalfe.   

Abstract

The effect of sulphasalazine on two mast cell populations and human peripheral leukocytes is reported. Sulphasalazine inhibited histamine release from mouse and rat mast cells, but it caused a potentiation of secretion in human peripheral leukocytes. The drug alone did not induce histamine release when administered without an anaphylactic stimulus. The results are discussed in terms of a possible mode of action of sulphasalazine in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579829     DOI: 10.1016/0014-2999(85)90071-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 3.  Mast cell polymorphisms. Present concepts, future directions.

Authors:  D Befus; H Fujimaki; T D Lee; M Swieter
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

Review 4.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

5.  Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid.

Authors:  C C Fox; W C Moore; L M Lichtenstein
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

6.  Sulphasalazine and experimental stress ulcers.

Authors:  C W Ogle; C H Cho; S Dai
Journal:  Agents Actions       Date:  1985-12

7.  The protective effects of sulphasalazine against ethanol-induced gastric damage in rats.

Authors:  C H Cho; C W Ogle; E L Sevilla
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

8.  Sulphasalazine and regression of rheumatoid nodules.

Authors:  H J Englert; G R Hughes; M J Walport
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

9.  Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.

Authors:  N Feltelius; R Hällgren
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

10.  Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.

Authors:  B Crotty; W M Rosenberg; J K Aronson; D P Jewell
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.